期刊
THROMBOSIS RESEARCH
卷 126, 期 1, 页码 E23-E29出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2010.04.003
关键词
EP receptors; Platelet aggregation; Platelet reactivity; Prostaglandin E(2); Thromboxane
资金
- NHLBI NIH HHS [5P50HL081009, P50 HL081009-04, P50 HL081009] Funding Source: Medline
- NIDDK NIH HHS [DK37097, R01 DK037097, R01 DK037097-24] Funding Source: Medline
- NIGMS NIH HHS [T32 GM007569, 5T32GM07569, 5T32GM07569-32, T32 GM007569-32] Funding Source: Medline
Introduction: Platelet hyperreactivity associates with cardiovascular events in humans. Studies in mice and humans suggest that prostaglandin E(2) (PGE(2)) regulates platelet activation. In mice, activation of the PGE(2) receptor subtype 3 (EP3) promotes thrombosis, but the significance of EP3 in humans is less well understood. Objectives: To characterize the regulation of thromboxane-dependent human platelet activation by PGE(2). Patients/Methods: Platelets collected from nineteen healthy adults were studied using an agonist of the thromboxane receptor (U46,619), PGE(2), and selective agonists and/or antagonists of the EP receptor subtypes. Platelet activation was assayed by (1) optical aggregometry, (2) measurement of dense granule release, and (3) single-platelet counting. Results: Healthy volunteers demonstrated significant interindividual variation in platelet response to PGE(2). PGE(2) completely inhibited U46,619-induced platelet aggregation and ATP release in 26% of subjects; the remaining 74% had partial or no response to PGE(2). Antagonism of EP4 abolished the inhibitory effect of PGE(2). In all volunteers, a selective EP2 agonist inhibited U46,619-induced aggregation. Furthermore, the selective EP3 antagonist DG-041 converted all PGE(2) nonresponders to full responders. Conclusions: There is significant interindividual variation of platelet response to PGE(2) in humans. The balance between EP2, EP3, and EP4 activation determines its net effect. PGE(2) can prevent thromboxane-induced platelet aggregation in an EP4-dependent manner. EP3 antagonism converts platelets of nonresponders to a PGE(2)-responsive phenotype. These data suggest that therapeutic targeting of EP pathways may have cardiovascular benefit by decreasing platelet reactivity. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据